{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:40:39Z","timestamp":1792478439898,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06200-x","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T18:20:45Z","timestamp":1748456445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hyperprolactinemia in children and adolescents: clinical characteristics and etiological spectrum"],"prefix":"10.1007","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-7908","authenticated-orcid":false,"given":"Fatih","family":"Kilci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7355-5408","authenticated-orcid":false,"given":"Emre","family":"Sarikaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1706-8012","authenticated-orcid":false,"given":"Nurhan \u00d6zcan","family":"Murat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9385-3787","authenticated-orcid":false,"given":"Adnan","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6741-2929","authenticated-orcid":false,"given":"\u0130hsan","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4054-063X","authenticated-orcid":false,"given":"U\u011fur","family":"Sar\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"6200_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000284359","volume":"73","author":"L Saranac","year":"2010","unstructured":"Saranac L, Zivanovic S, Radovanovic Z et al (2010) Hyperprolactinemia: different clinical expression in childhood. Horm Res Paediatr 73:187\u2013192. https:\/\/doi.org\/10.1159\/000284359","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"6200_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.23750\/abm.v90i1.8142","volume":"90","author":"M Matalliotakis","year":"2019","unstructured":"Matalliotakis M, Koliarakis I, Matalliotaki C et al (2019) Clinical manifestations, evaluation and management of hyperprolactinemia in adolescent and young girls: a brief review. Acta Biomed 90(1):149\u2013157. https:\/\/doi.org\/10.23750\/abm.v90i1.8142","journal-title":"Acta Biomed"},{"issue":"2","key":"6200_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4274\/jcrpe.galenos.2018.2018.0206","volume":"11","author":"E Eren","year":"2019","unstructured":"Eren E, T\u00f6relErg\u00fcr A, \u0130\u015fg\u00fcven \u015eP et al (2019) Clinical and laboratory characteristics of hyperprolactinemia in children and adolescents: national survey. J Clin Res Pediatr Endocrinol 11(2):149\u2013156. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2018.2018.0206","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"1","key":"6200_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000499694","volume":"109","author":"L Vilar","year":"2019","unstructured":"Vilar L, Vilar CF, Lyra R, Freitas MDC (2019) Pitfalls in the diagnostic evaluation of hyperprolactinemia. Neuroendocrinology 109(1):7\u201319. https:\/\/doi.org\/10.1159\/000499694","journal-title":"Neuroendocrinology"},{"issue":"2","key":"6200_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.20945\/2359-39970000000270","volume":"62","author":"L Vilar","year":"2018","unstructured":"Vilar L, Abucham J, Albuquerque JL et al (2018) Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the neuroendocrinology department of the Brazilian society of endocrinology and metabolism. Arch Endocrinol Metab 62(2):236\u2013263. https:\/\/doi.org\/10.20945\/2359-39970000000270","journal-title":"Arch Endocrinol Metab"},{"key":"6200_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/B978-1-4160-5583-9.00018-6","volume-title":"Endocrinology","author":"MD Bronstein","year":"2010","unstructured":"Bronstein MD (2010) Disorders of prolactin secretion and prolactinomas. In: DeGroot LJ, Jameson JL (eds) Endocrinology, 6th edn. Saunders\/Elsevier, Philadelphia, pp 333\u2013357","edition":"6"},{"issue":"Suppl 1","key":"6200_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0306-4530(02)00112-9","volume":"28","author":"U Halbreich","year":"2003","unstructured":"Halbreich U, Kinon BJ, Gilmore JA, Kahn LS (2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28(Suppl 1):53\u201367. https:\/\/doi.org\/10.1016\/s0306-4530(02)00112-9","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"6200_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12020-009-9279-7","volume":"37","author":"JW Hong","year":"2010","unstructured":"Hong JW, Lee MK, Kim SH, Lee EJ (2010) Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma. Endocrine 37(1):140\u2013147. https:\/\/doi.org\/10.1007\/s12020-009-9279-7","journal-title":"Endocrine"},{"issue":"1","key":"6200_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19(1):41\u201347. https:\/\/doi.org\/10.1093\/humrep\/deh098","journal-title":"Hum Reprod"},{"key":"6200_CR10","doi-asserted-by":"crossref","unstructured":"Samson SL, Hamrahian AH, Ezzat S; AACE Neuroendocrine and Pituitary Scientific Committee; American College of Endocrinology (ACE). (2015) American association of clinical endocrinologists, American college of endocrinology disease state clinical review: Clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia. Endocr Pract 21:1427\u20131435","DOI":"10.4158\/EP15938.DSC"},{"issue":"3","key":"6200_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/s0889-8529(05)70203-6","volume":"30","author":"ME Molitch","year":"2001","unstructured":"Molitch ME (2001) Disorders of prolactin secretion. Endocrinol Metab Clin North Am 30(3):585\u2013610. https:\/\/doi.org\/10.1016\/s0889-8529(05)70203-6","journal-title":"Endocrinol Metab Clin North Am"},{"key":"6200_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4274\/jcrpe.2183","volume":"7","author":"O Neyzi","year":"2015","unstructured":"Neyzi O, Bundak R, G\u00f6k\u00e7ay G et al (2015) Reference values for weight, height, head circumference, and body mass index in Turkish children. J Clin Res Pediatr Endocrinol 7:280\u2013293. https:\/\/doi.org\/10.4274\/jcrpe.2183","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"5","key":"6200_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/BF03346388","volume":"31","author":"L Vilar","year":"2008","unstructured":"Vilar L, Freitas MC, Naves LA et al (2008) Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest 31(5):436\u2013444","journal-title":"J Endocrinol Invest"},{"key":"6200_CR14","doi-asserted-by":"publisher","unstructured":"Kontbay T, \u015e\u0131klar Z, \u00d6zsu E, et al. (2022) Hyperprolactinemia in children and adolescents and long-term follow-up results of prolactinoma cases: a single-centre experience. Turk J Pediatr 64(5):892\u2013899. https:\/\/doi.org\/10.24953\/turkjped.2021.4639","DOI":"10.24953\/turkjped.2021.4639"},{"issue":"11","key":"6200_CR15","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1515\/cclm.2002.202","volume":"40","author":"MW Elmlinger","year":"2002","unstructured":"Elmlinger MW, K\u00fchnel W, Ranke MB (2002) Reference ranges for serum concentrations of lutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and young adults. Clin Chem Lab Med 40(11):1151\u20131160. https:\/\/doi.org\/10.1515\/cclm.2002.202","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"6200_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3109\/00365513.2012.667571","volume":"72","author":"M Aldrimer","year":"2012","unstructured":"Aldrimer M, Ridefelt P, R\u00f6d\u00f6\u00f6 P et al (2012) Reference intervals on the Abbot Architect for serum thyroid hormones, lipids and prolactin in healthy children in a population-based study. Scand J Clin Lab Invest 72(4):326\u2013332","journal-title":"Scand J Clin Lab Invest"},{"key":"6200_CR17","doi-asserted-by":"publisher","unstructured":"Vilar L, Vilar CF, Lyra R, et al. (2024) Usefulness of prolactin levels in predicting the etiology of hyperprolactinemia in a cohort of 770 patients. Arch Endocrinol Metab 68:e230391. Published 2024 Sep 11. https:\/\/doi.org\/10.20945\/2359-4292-2023-0391","DOI":"10.20945\/2359-4292-2023-0391"},{"issue":"3","key":"6200_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11102-008-0115-9","volume":"12","author":"SV Acharya","year":"2009","unstructured":"Acharya SV, Gopal RA, Bandgar TR et al (2009) Clinical profile and long-term follow-up of children and adolescents with prolactinomas. Pituitary 12(3):186\u2013189. https:\/\/doi.org\/10.1007\/s11102-008-0115-9","journal-title":"Pituitary"},{"key":"6200_CR19","doi-asserted-by":"publisher","unstructured":"Kilci F, Sarikaya E, Murat N\u00d6 et al (2025) Etiology, presentation, and outcomes of hyperprolactinemia due to pituitary masses in children and adolescents. Endocrine. Published online February 2, 2025. https:\/\/doi.org\/10.1007\/s12020-025-04176-0","DOI":"10.1007\/s12020-025-04176-0"},{"issue":"7","key":"6200_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1055\/s-0035-1550018","volume":"123","author":"R Stawerska","year":"2015","unstructured":"Stawerska R, Smyczy\u0144ska J, Hilczer M et al (2015) Does elevated morning prolactin concentration in children always mean the diagnosis of hyperprolactinemia? Exp Clin Endocrinol Diabetes 123(7):405\u2013410. https:\/\/doi.org\/10.1055\/s-0035-1550018","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"6200_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6200_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12020-023-03523-3","volume":"83","author":"F Kilci","year":"2024","unstructured":"Kilci F, Jones JH, \u00c7akl\u0131l\u0131 M et al (2024) Clinical and therapeutic outcomes of pediatric pituitary adenomas: a single pituitary center experience. Endocrine 83(1):160\u2013170. https:\/\/doi.org\/10.1007\/s12020-023-03523-3","journal-title":"Endocrine"},{"issue":"2\u20133","key":"6200_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ando.2007.03.013","volume":"68","author":"C Cortet-Rudelli","year":"2007","unstructured":"Cortet-Rudelli C, Sapin R, Bonneville JF, Brue T (2007) Etiological diagnosis of hyperprolactinemia. Ann Endocrinol (Paris) 68(2\u20133):98\u2013105","journal-title":"Ann Endocrinol (Paris)"},{"key":"6200_CR24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/archinte.1983.00350070103017","volume":"143","author":"H Gharib","year":"1983","unstructured":"Gharib H, Frey HM, Laws ER Jr, Randall RV, Scheithauer BW (1983) Coexistent primary empty sella syndrome and hyperprolactinemia. Arch Intern Med 143:1383\u20131386","journal-title":"Arch Intern Med"},{"key":"6200_CR25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00865-y","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement. Nat Rev Endocrinol 19:722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00865-y","journal-title":"Nat Rev Endocrinol"},{"key":"6200_CR26","doi-asserted-by":"publisher","first-page":"883092","DOI":"10.3389\/fendo.2022.883092","volume":"13","author":"F Lopez-Vicchi","year":"2022","unstructured":"Lopez-Vicchi F, De Winne C, Ornstein AM et al (2022) Severe hyperprolactinemia promotes brown adipose tissue whitening and aggravates high fat diet induced metabolic imbalance. Front Endocrinol (Lausanne) 13:883092. https:\/\/doi.org\/10.3389\/fendo.2022.883092","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6200_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","volume":"147","author":"M Doknic","year":"2002","unstructured":"Doknic M, Pekic S, Zarkovic M et al (2002) Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 147:77\u201384. https:\/\/doi.org\/10.1530\/eje.0.1470077","journal-title":"Eur J Endocrinol"},{"key":"6200_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1758-5996-6-104","volume":"6","author":"M Ezrokhi","year":"2014","unstructured":"Ezrokhi M, Luo S, Trubitsyna Y et al (2014) Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr 6:104. https:\/\/doi.org\/10.1186\/1758-5996-6-104","journal-title":"Diabetol Metab Syndr"},{"key":"6200_CR29","doi-asserted-by":"publisher","unstructured":"Delcour C, Robin G, Young J, et al. (2019) PCOS and hyperprolactinemia: what do we know in 2019? Clin Med Insights Reprod Health 13:1179558119871921. https:\/\/doi.org\/10.1177\/1179558119871921. Published 2019 Sep 9","DOI":"10.1177\/1179558119871921"},{"issue":"1","key":"6200_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.advms.2021.12.003","volume":"67","author":"F Mahboobifard","year":"2022","unstructured":"Mahboobifard F, Rahmati M, Amiri M et al (2022) To what extent does polycystic ovary syndrome influence the cut-off value of prolactin? Findings of a community-based study. Adv Med Sci 67(1):79\u201386","journal-title":"Adv Med Sci"},{"issue":"6","key":"6200_CR31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s11154-024-09912-x","volume":"25","author":"N Cera","year":"2024","unstructured":"Cera N, Pinto J, Pignatelli D (2024) What do we know about abnormally low prolactin levels in polycystic ovary syndrome? A narrative review. Rev Endocr Metab Disord 25(6):1127\u20131138. https:\/\/doi.org\/10.1007\/s11154-024-09912-x","journal-title":"Rev Endocr Metab Disord"},{"issue":"18","key":"6200_CR32","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.26355\/eurrev_202309_33748","volume":"27","author":"M Amin","year":"2023","unstructured":"Amin M, Wu R, Postolache TT, Gragnoli C (2023) Linkage and association of novel DRD2 variants to the comorbidity of type 2 diabetes and depression. Eur Rev Med Pharmacol Sci 27(18):8322. https:\/\/doi.org\/10.26355\/eurrev_202309_33748","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"6200_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13048-023-01205-2","volume":"16","author":"M Amin","year":"2023","unstructured":"Amin M, Horst N, Gragnoli C (2023) Linkage and association of variants in the dopamine receptor 2 gene (DRD2) with polycystic ovary syndrome. J Ovarian Res 16(1):158. https:\/\/doi.org\/10.1186\/s13048-023-01205-2","journal-title":"J Ovarian Res"},{"issue":"1","key":"6200_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0015-0282(16)49094-1","volume":"45","author":"P Serafini","year":"1986","unstructured":"Serafini P, Lobo RA (1986) Prolactin modulates peripheral androgen metabolism. Fertil Steril 45(1):41\u201346","journal-title":"Fertil Steril"},{"issue":"5","key":"6200_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1055\/s-2008-1081209","volume":"117","author":"F Kelestimur","year":"2009","unstructured":"Kelestimur F, Everest H, Dundar M, Tanriverdi F, White C, Witchel SF (2009) The frequency of CYP 21 gene mutations in Turkish women with hyperandrogenism. Exp Clin Endocrinol Diabetes 117(5):205\u2013208. https:\/\/doi.org\/10.1055\/s-2008-1081209","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"6200_CR36","unstructured":"Kolnikaj TS, Musat M, Salehidoost R et al (2024) Pharmacological causes of hyperprolactinemia. In: Feingold KR (ed) Endotext. South Dartmouth (MA): MDText.com, Inc.; January 4, 2024"},{"issue":"Pt 3","key":"6200_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/000456329703400305","volume":"34","author":"MN Fahie-Wilson","year":"1997","unstructured":"Fahie-Wilson MN, Soule SG (1997) Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 34(Pt 3):252\u2013258","journal-title":"Ann Clin Biochem"},{"key":"6200_CR38","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/jcem.87.2.8272","volume":"87","author":"S Vallette-Kasik","year":"2002","unstructured":"Vallette-Kasik S, Morange-Ramos I, Selim A et al (2002) Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 87:581\u2013588","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"6200_CR39","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1805171","volume":"379","author":"T Kobayashi","year":"2018","unstructured":"Kobayashi T, Usui H, Tanaka H et al (2018) Variant prolactin receptor in Agalactia and Hyperprolactinemia. N Engl J Med 379(23):2230\u20132236. https:\/\/doi.org\/10.1056\/NEJMoa1805171","journal-title":"N Engl J Med"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06200-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06200-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06200-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:02:39Z","timestamp":1749459759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06200-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["6200"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06200-x","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Kocaeli City Hospital (approval number: 2024\/107).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"366"}}